# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7698502

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ABBVIE DEUTSCHLAND GMBH & CO. KG	08/17/2022

### **RECEIVING PARTY DATA**

Name:	ABBVIE INC.	
Street Address:	1 NORTH WAUKEGAN ROAD	
City:	NORTH CHICAGO	
State/Country:	ILLINOIS	
Postal Code:	60064	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	17712008

### **CORRESPONDENCE DATA**

**Fax Number:** (857)302-6843

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 857 287-3100

Email: Maureen.Tierney@wbd-us.com

Correspondent Name: WOMBLE BOND DICKINSON (US) LLP

Address Line 1: INDEPENDENCE WHARF 470 ATLANTIC AVENUE

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	ABV12353USC2/1310US.C2T1	
NAME OF SUBMITTER:	MAUREEN TIERNEY	
SIGNATURE:	/Maureen Tierney/	
DATE SIGNED:	12/16/2022	

## **Total Attachments: 3**

source=ABV12353USP1 - GmbH to AbbVie Inc Assignment#page1.tif source=ABV12353USP1 - GmbH to AbbVie Inc Assignment#page2.tif source=ABV12353USP1 - GmbH to AbbVie Inc Assignment#page3.tif

PATENT 507651367 REEL: 062119 FRAME: 0860

#### **ASSIGNMENT**

AbbVie Deutschland GmbH & Co. KG, a corporation organized and existing under the laws of Germany having a place of business at Mainzer Str. 81, 65189 Wiesbaden, Germany, hereinafter the "Assignor", has made certain new and useful inventions as described in:

US patent application 17/667,748, filed on February 9, 2022, entitled ""METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS" {Atty. Docket No. 12353USP1 (A103017 1310 US.CP1 0796.5)};

WHEREAS, AbbVie Inc., a corporation organized and existing under the laws of Delaware, USA, having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064, USA, hereinafter the "Assignee", desires to acquire the entire right, title and interest in and to the inventions and the patent application(s) identified above, and all patents, foreign and domestic, which may be obtained for said inventions, and Assignor desires to assign such rights to AbbVie Inc., as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the receipt of which is hereby acknowledged:

- 1, The Assignor has sold, conveyed, assigned and transferred, and by these presents do sell, convey, assign and transfer, to the Assignee its entire right, title and interest for the United States and all other jurisdictions in and to the inventions and the patent application(s) identified above, and any patents that may issue for said inventions, together with all patent applications, patents, utility models and designs therefore, including without limitation all continuations, divisions, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and any substitute applications thereof, including the full right to claim all benefits and priority rights thereto under any applicable convention or treaty including without limitation the Paris Convention, and all rights of action arising from the foregoing, including without limitation all claims for damages by reason of present, past and future infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing, in each case, to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns.
- 2, The Assignor hereby covenants and agrees that Assignor has the full right to convey the interests granted by this Assignment; and that the Assignor will assist the Assignee (including prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the

extent deemed necessary or desirable by Assignee) in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the inventions identified above, in vesting in the Assignee with exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in the defense and enforcement of any rights arising out of such patent application or patent, or this Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Assignment.

3, The terms and covenants of this Assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor and its respective heirs, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignor executes this Assignment.

AbbVie Deutschland GmbH & Co. KG

ppa. Dr. Stephan Bensiek

ppa. Axel Flach

Senior Authorized Officers

<u>Aug 17, 2022</u>

The Assignee accepts this Assignment.

AbbVie Inc.

Johanna Corbin

VP, Intellectual Property and Strategy

26.001-2022

Date

Page 3 of 3